Turalio
Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour
August 5, 2019Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer
Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
